Abstract:Immunotherapy using immune checkpoint inhibitors (ICIs) has emerged as one of the most potent cancer therapies. However, low response rates to ICI therapeutics, particularly in solid tumors, have been observed in clinical practice because of several factors, with the poor immunogenic condition of the tumor microenvironment (TME) being considered a key feature. In this study, we flamed up the TME of solid tumors by using LTX-315 (LTX), a first-in-class oncolytic cationic peptide, and an RNA drug, poly(I:C) (IC), Toll-like receptor (TLR) 3 agonist, to boost the therapeutic effect of anti-PD-1 (aPD1) therapy. Intelligent hybrid nanoparticles (NPs) were designed and fabricated with the decoration of CD47 mimicking peptide (CD47p) (LTX/IC-NP@CD47p) on their surfaces to suppress phagocytosis of phagocytes and enhance the persistence of NPs in the circulatory system, followed by improved accumulation in tumor tissue and a higher cellular uptake capacity of cancer cells. The results demonstrated that LTX/IC-NP@CD47p effectively triggered immunogenic cell death (ICD) in vitro and in vivo characterized by abundant damage-associated molecular pattern (DAMP) levels and robustly induced type I interferon release, which enhanced the immune condition of solid tumors with increased antitumor effector immune cells, supporting the therapeutic effect of aPD1 therapy. Moreover, the combination of LTX/IC-NP@CD47p treatment and aPD1 therapy inhibited tumor metastasis by reducing the epithelial-mesenchymal transition (EMT) in primary tumors, which prolonged the survival rate of tumor-bearing mice in the in vivo model. Thus, our study suggests a potent strategy for improving therapeutic efficacy of ICIs by combining an ICD inducer and TLR agonist to induce a highly immunogenic TME.

T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy

When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy

A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy

Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance

Innate Immunomodulatory Nanodevices for Cancer Therapy: A Review

A “three musketeers” tactic for inclining interferon-γ as a comrade-in-arm to reinforce the synergistic-tumoricidal therapy

Engineered Cell-Membrane-Coated Nanoparticles Directly Present Tumor Antigens to Promote Anticancer Immunity.

Cancer cell membrane–encapsulated biomimetic nanoparticles for tumor immuno-photothermal therapy

Nanoengineered Targeting Strategy for Cancer Immunotherapy

Immunocyte Membrane-Coated Nanoparticles for Cancer Immunotherapy

A nano-innate immune system activator for cancer therapy in a 4T1 tumor-bearing mouse model

Toll-like Receptor-Targeted Nanoparticles: A Powerful Combination for Tumor Immunotherapy

Nanovesicles loaded with a TGF-β receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy

Tumor and Dendritic Cell Dual-Targeting Nanocarriers Maximize the Therapeutic Potential of IDO1 Inhibitor in Vivo

Engineering interferons for cancer immunotherapy

Tumor Microenvironment‐Responsive Nanoparticles Amplifying STING Signaling Pathway for Cancer Immunotherapy

Reigniting the cancer-immunity cycle with nanoparticles for simultaneous delivery of oncolytic peptides and a TLR agonist

Targeting type I interferon tumor entry by anti-PD-L1 creates feedforward antitumor responses to overcome innate and adaptive resistance

Biointerfacing Antagonizing T‐Cell Inhibitory Nanoparticles Potentiate Hepatocellular Carcinoma Checkpoint Blockade Therapy (Small 51/2021)

Engineering Nanoparticles to Reprogram the Tumor Immune Microenvironment for Improved Cancer Immunotherapy

Nanoparticles (NPs)-mediated Siglec15 silencing and macrophage repolarization for enhanced cancer immunotherapy